Objective To investigate the median effective dose(ED50)and 95％effective dose(ED95)of ciprofol in combination with butorphanol for painless gastroscopy in elderly patients.Meth-ods A total of 27 elderly patients with selective gastroscopy were conducted with intravenous induc-tion of 5 μg/kg butorphanol for at least 30 seconds,and 3 minutes later,they were administered intra-venously with ciprofol for at least 30 seconds;gastroscopy was performed when the eyelash reflex disap-peared or the Modified Observers Assessment of Alertness/Sedation(MOAA/S)score was less than one point.The initial dose of ciprofol was set as 0.2 mg/kg,and the modified sequential allocation method was used;if there was a positive response during the insertion of the gastroscope,the dose for the next patient would increase by one level,and vice versa,the dose would decrease by one level,with an adjacent dose concentration gradient of 0.05 mg/kg.A positive response to gastroscope inser-tion was defined as coughing,swallowing,or limb movements when the gastroscope entered the throat.The study was terminated after 7 reversals in ciprofol dose adjustments.ED50,ED95,and correspond-ing 95％confidence intervals(95％CI)of ciprofol combined with butorphanol for painless gastroscopy were calculated.Results When combined with butorphanol,the ED50 of ciprofol for painless gastrosco-py in elderly patients was 0.253 mg/kg(95％CI,0.219 to 0.290),and the ED95 was 0.328 mg/kg(95％CI,0.290 to 0.521).Conclusion When combined with butorphanol,the ED50 of ciprofol for painless gastroscopy in elderly patients is 0.253 mg/kg,and the ED95 is 0.328 mg/kg.

Objective To investigate the median effective dose(ED50)and 95％effective dose(ED95)of ciprofol in combination with butorphanol for painless gastroscopy in elderly patients.Meth-ods A total of 27 elderly patients with selective gastroscopy were conducted with intravenous induc-tion of 5 μg/kg butorphanol for at least 30 seconds,and 3 minutes later,they were administered intra-venously with ciprofol for at least 30 seconds;gastroscopy was performed when the eyelash reflex disap-peared or the Modified Observers Assessment of Alertness/Sedation(MOAA/S)score was less than one point.The initial dose of ciprofol was set as 0.2 mg/kg,and the modified sequential allocation method was used;if there was a positive response during the insertion of the gastroscope,the dose for the next patient would increase by one level,and vice versa,the dose would decrease by one level,with an adjacent dose concentration gradient of 0.05 mg/kg.A positive response to gastroscope inser-tion was defined as coughing,swallowing,or limb movements when the gastroscope entered the throat.The study was terminated after 7 reversals in ciprofol dose adjustments.ED50,ED95,and correspond-ing 95％confidence intervals(95％CI)of ciprofol combined with butorphanol for painless gastroscopy were calculated.Results When combined with butorphanol,the ED50 of ciprofol for painless gastrosco-py in elderly patients was 0.253 mg/kg(95％CI,0.219 to 0.290),and the ED95 was 0.328 mg/kg(95％CI,0.290 to 0.521).Conclusion When combined with butorphanol,the ED50 of ciprofol for painless gastroscopy in elderly patients is 0.253 mg/kg,and the ED95 is 0.328 mg/kg.

OBJECTIVE: To assess the value of using flat-sided culture tubes for preparing chromosomes through chorionic villi (CV) and amniotic fluid (AF) cell cultures during prenatal diagnosis. METHODS: From February to March 2020, 157 CV samples and 147 AF samples subjected to prenatal diagnosis at the Maternal and Child Health Care Hospital of Guangxi Zhuang Autonomous Region were selected as the study subjects. For each sample, one flat-sided tube and one flask culture were set up by following the standard protocols. The methods were evaluated by comparing the cell growth, experimental process, quality of chromosome preparation and costs. RESULTS: The success rates for the culturing of CV and AF samples by the flat-sided culture tube method were 97.45% (153/157) and 97.96% (144/147), respectively. By contrast, the success rates for the conventional flask method were 98.72% (155/157) for CV and 98.64% (145/147) for AF samples. No significant difference was found between the two methods (P > 0.05). The average harvest time required by the flat-sided culture tube method was 8.45 days for CV and 9.43 days for AF cultures, whilst the average harvest time for conventional flask method was 9.05 days and 9.54 days, respectively. The flat-sided culture tube method for CV had required significantly shorter average harvest time than the conventional method (P < 0.001). No statistical significant difference was found in the average harvest time for AF by the two methods (P > 0.05). The conventional culturing method had required three containers with two sample transfers. By contrast, the flat-sided culture tube method was carried out in one tube without any sample transfer. The average total amount of medium used was 3.91 mL for each flat-sided culture tube and 6.26 mL for each conventional flask. CONCLUSION The flat-sided culture tube method can provide a simple, cost-effective and error-reducing procedure for the CV and AF samples culture during prenatal diagnosis.
Child ; Female ; Pregnancy ; Humans ; China ; Prenatal Diagnosis ; Chorionic Villi Sampling ; Amniotic Fluid ; Cell Proliferation

This phase I clinical trial (NCT01935843) is to evaluate the safety, feasibility, and activity of chimeric antigen receptor-engineered T cell (CART) immunotherapy targeting human epidermal growth factor receptor 2 (HER2) in patients with advanced biliary tract cancers (BTCs) and pancreatic cancers (PCs). Eligible patients with HER2-positive (>50%) BTCs and PCs were enrolled in the trial. Well cultured CART-HER2 cells were infused following the conditioning treatment composed of nab-paclitaxel (100-200 mg/m) and cyclophosphamide (15-35 mg/kg). CAR transgene copy number in the peripheral blood was serially measured to monitor the expansion and persistence of CART-HER2 cells in vivo. Eleven enrolled patients received 1 to 2-cycle CART-HER2 cell infusion (median CAR T cell 2.1 × 10/kg). The conditioning treatment resulted in mild-to-moderate fatigue, nausea/vomiting, myalgia/arthralgia, and lymphopenia. Except one grade-3 acute febrile syndrome and one abnormal elevation of transaminase (>9 ULN), adverse events related to the infusion of CART-HER2 cells were mild-to-moderate. Post-infusion toxicities included one case of reversible severe upper gastrointestinal hemorrhage which occurred in a patient with gastric antrum invaded by metastasis 11 days after the CART-HER2 cell infusion, and 2 cases of grade 1-2 delayed fever, accompanied by the release of C-reactive protein and interleukin-6. All patients were evaluable for assessment of clinical response, among which 1 obtained a 4.5-months partial response and 5 achieved stable disease. The median progression free survival was 4.8 months (range, 1.5-8.3 months). Finally, data from this study demonstrated the safety and feasibility of CART-HER2 immunotherapy, and showed encouraging signals of clinical activity.
Aged ; Biliary Tract Neoplasms ; immunology ; therapy ; Female ; Humans ; Immunotherapy, Adoptive ; Male ; Middle Aged ; Pancreatic Neoplasms ; immunology ; therapy ; Receptor, ErbB-2 ; immunology ; Receptors, Chimeric Antigen ; immunology ; T-Lymphocytes ; immunology